 |
|
|
| Éditorial |
|
Les mutations Kras et le traitement ciblé dans les carcinomes bronchiques non à petites cellules et les cancers colorectaux
C Massard, T André
|
 Article gratuit
|
|
| Synthèse |
|
Mouse models of K-ras-initiated oncogenesis
C Barrière, F El Marjou, D Louvard, S Robine
|
Résumé
Article gratuit
 Summary
|
Technical considerations for KRAS testing in colorectal cancer. The pathologist’s point of view
F Bibeau, H Frugier, A Denouel, J-C Sabourin, F Boissiere-Michot
|
Résumé
Article gratuit
Summary
|
Pronostic role of KRAS mutation in colorectal cancer
F Di Fiore, P Michel
|
Résumé
Article gratuit
Summary
|
Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients
D Smith, C Bosacki, Y Merrouche
|
Résumé
Article gratuit
Summary
|
Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis
E Assenat, M Ychou
|
Résumé
Article gratuit
Summary
|
Technical considerations for KRAS testing in colorectal cancer. The biologist’s point of view
H Blons, P Laurent-Puig
|
Résumé
Article gratuit
Summary
|
Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value
D Planchard, Y Loriot, B Besse
|
Résumé
Article gratuit
Summary
|
Targeting KRAS pathway in NSCLC therapy
S Le Moulec, Y Loriot, J-C Soria
|
Résumé
Article gratuit
Summary
|
KRAS status versus EGFR status in lung cancer therapy
L Lacroix, B Besse, J-M Bidart, J Bosq
|
Résumé
Article gratuit
Summary
|
Cutaneous side effects of EGF receptor inhibitors
D Nassar, B Soutou, S Aractingi
|
Résumé
Article gratuit
Summary
|
|
